TP53 rs28934873: Understanding Li-Fraumeni Syndrome Risk
The rs28934873 variant is a specific genetic change located within the TP53 gene. It is clinically associated with an increased susceptibility to Li-Fraumeni Syndrome, a rare condition characterized by a higher lifetime risk of developing various types of cancer.
What each genotype means
Typical TP53 genotype
This is the common, non-pathogenic genotype for this location in the TP53 gene. It is considered the reference sequence and is not associated with the increased cancer risks linked to Li-Fraumeni syndrome.
This is the most common genotype found in the general population.
Increased cancer predisposition
This genotype involves a pathogenic variant in the TP53 gene, which is associated with a predisposition to Li-Fraumeni syndrome. Individuals with this genotype have a significantly higher lifetime risk of developing various cancers, including sarcomas, breast cancer, and brain tumors. Please consult with a genetic counselor or medical professional to discuss appropriate cancer surveillance and management strategies.
This genotype is rare in the general population.
What is rs28934873?
The variant rs28934873 is a single nucleotide polymorphism (SNP) located on chromosome 17 within the TP53 gene. In genetics, a SNP represents a variation at a single position in the DNA sequence. This specific variant is recognized in clinical databases for its potential impact on the function of the protein encoded by the TP53 gene. Because the TP53 gene is critical for maintaining genomic stability, changes in its sequence can have significant biological consequences. Researchers track this variant to understand how specific alterations in the genetic code may contribute to hereditary health conditions. It is important to note that while this variant is documented in scientific literature, its presence does not automatically guarantee the development of a disease, but rather indicates a predisposition that warrants clinical attention.
The Role of the TP53 Gene
The TP53 gene provides instructions for making a protein called p53, which acts as a tumor suppressor. This protein is often referred to as the 'guardian of the genome' because it plays a vital role in preventing cells from growing and dividing too rapidly or in an uncontrolled way. When DNA damage occurs, the p53 protein helps determine whether the cell should repair the damage or undergo programmed cell death, known as apoptosis. By regulating these processes, p53 prevents the accumulation of mutations that could lead to tumor formation. When a pathogenic variant occurs in the TP53 gene, the resulting p53 protein may lose its ability to effectively monitor cell health, thereby increasing the likelihood that damaged cells will continue to replicate and potentially form cancerous growths.
Research and Clinical Associations
Scientific research has established a strong link between pathogenic germline variants in the TP53 gene and Li-Fraumeni Syndrome (LFS). LFS is an autosomal dominant disorder, meaning that inheriting a single copy of a pathogenic variant from one parent is sufficient to increase cancer risk. Individuals with LFS exhibit a broad spectrum of cancer types, often at an earlier age than typically seen in the general population. The evidence supporting the classification of certain TP53 variants as pathogenic is derived from clinical observations of families with high incidences of cancer and functional assays that demonstrate the loss of p53 activity. While rs28934873 is associated with this predisposition, the clinical expression of LFS can be highly variable, even among family members who carry the same genetic variant.
Population Frequency and Prevalence
Li-Fraumeni Syndrome is considered a rare condition. Current estimates suggest that the prevalence of germline pathogenic TP53 variants in the general population ranges from approximately 1 in 3,000 to 1 in 10,000. Because this variant is rare, it is not commonly found in the general population compared to more frequent genetic polymorphisms. Most individuals do not carry this specific variant. Due to its rarity, large-scale population studies often have limited data on the exact frequency of rs28934873 across diverse ancestral groups. The clinical significance of this variant is primarily determined through targeted genetic testing in individuals or families who meet specific clinical criteria for cancer predisposition syndromes, rather than through routine population screening.
Managing Genetic Information
If you have received information regarding the rs28934873 variant, it is essential to understand that this is not a medical diagnosis. Genetic test results should always be interpreted by a qualified healthcare professional, such as a genetic counselor or an oncologist, who can place the findings in the context of your personal and family medical history. A positive result for a pathogenic variant does not mean that cancer is inevitable, but it may lead to recommendations for increased cancer surveillance or specialized screening protocols. You should never make medical decisions based solely on raw genetic data. If you are concerned about your risk, consult with a clinician to discuss appropriate testing, surveillance options, and the potential implications for your family members.
How common is this variant?
The rs28934873 variant is rare, with pathogenic germline TP53 variants estimated to occur in approximately 1 in 3,000 to 1 in 10,000 individuals in the general population.
Frequently asked questions
What is Li-Fraumeni Syndrome?
Li-Fraumeni Syndrome is a rare, inherited disorder that significantly increases the risk of developing various types of cancer at a younger age. It is primarily caused by pathogenic variants in the TP53 gene.
Does having this variant mean I will get cancer?
No, having a genetic variant associated with Li-Fraumeni Syndrome does not mean you will definitely develop cancer. It indicates a higher susceptibility, and you should discuss your specific risk profile with a genetic counselor.
Should I get tested for this variant?
Genetic testing for TP53 variants is typically recommended for individuals who meet specific clinical criteria, such as a strong family history of early-onset cancers. You should consult with a healthcare provider to determine if testing is appropriate for you.
What should I do if I have this variant?
If you are found to carry a pathogenic TP53 variant, you should work with a medical team specializing in cancer genetics. They can help you develop a personalized surveillance plan to monitor your health.
Sources & further reading
Educational information only, last refreshed 9/17/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs28934873?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in TP53
Pathogenic missense variant (p.Arg248Gln) associated with Li-Fraumeni syndrome.
Functional codon 72 polymorphism (Arg72Pro) affecting apoptotic capability and associated with differential susceptibility to multiple cancer types.
Functional 3' UTR polyadenylation signal polymorphism altering TP53 transcription termination, showing population-specific baseline carrier frequencies across global groups.
Pathogenic hotspot variant (p.Arg273His) in TP53 predisposing carriers to early-onset sarcomas, breast cancers, and leukemias.
Li-Fraumeni syndrome missense variant (p.Arg248Trp) causing loss of tumor suppressor function and multi-cancer predisposition.
Synonymous and regulatory variant in linkage with TP53 codon 72 that modulates blastocyst implantation competence and the risk of recurrent implantation failure.